Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma

Matias E. Valsecchi, Misti Coronel, Charles M. Intenzo, Sung M. Kim, Agnieszka K. Witkiewicz, Takami Sato

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

As uveal melanoma originates in the neural crest, we aimed to explore whether somatostatin receptor (SSTR) expression is present and plays any role in these patients. Heavily pretreated metastatic uveal melanoma patients were tested with somatostatin receptor scintigraphy (SRS). Planar images of the whole body complemented by single-photon emission computed tomography on suspected sites were acquired between 4 and 24 h after an intravenous administration of 185-222 MBq (5-6 mCi) of indium-octeotride. SSTR expression in metastatic tissues was confirmed by immunohistochemistry. In seven patients, sandostatin LAR was used with therapeutic intention. Thirty white patients were tested. All had extensive metastatic disease and the median number of previous treatments was three. SRS was found to be positive in 14 (46%) of the patients, but was not related to sex, type of previous treatments, tumor site, or histological type. In 10 patients, sufficient tumor specimens were available to perform immunohistochemical staining for SSTR. All cases with positive SSTR-2A staining were also positive by SRS. Two of the seven patients who received sandostatin LAR died within a month after receiving the first dose, whereas another two (28.5%) had stable disease for more than 5 months. The median time to progression after starting sandostatin was 2.1 months (range: 0.2-5.5 months). Approximately 50% of the uveal melanoma patients with extensive metastatic disease were positive for SSR, which was consistent with immunohistochemical staining for SSTR-2A. Therapeutic approaches targeting SSTR might be beneficial in patients with metastatic uveal melanoma.

Original languageEnglish (US)
Pages (from-to)33-39
Number of pages7
JournalMelanoma Research
Volume23
Issue number1
DOIs
StatePublished - Feb 2013

Fingerprint

Somatostatin Receptors
Radionuclide Imaging
Octreotide
Staining and Labeling
Uveal melanoma
Indium
Neural Crest
Body Image
Therapeutics
Single-Photon Emission-Computed Tomography
Intravenous Administration
Neoplasms
Immunohistochemistry

Keywords

  • Sandostatin
  • Scintigraphy
  • Somatostatin
  • Somatostatin receptor-2
  • Uveal melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology

Cite this

Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. / Valsecchi, Matias E.; Coronel, Misti; Intenzo, Charles M.; Kim, Sung M.; Witkiewicz, Agnieszka K.; Sato, Takami.

In: Melanoma Research, Vol. 23, No. 1, 02.2013, p. 33-39.

Research output: Contribution to journalArticle

Valsecchi, Matias E. ; Coronel, Misti ; Intenzo, Charles M. ; Kim, Sung M. ; Witkiewicz, Agnieszka K. ; Sato, Takami. / Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. In: Melanoma Research. 2013 ; Vol. 23, No. 1. pp. 33-39.
@article{c14514168e434b4ba7a2443755da39d8,
title = "Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma",
abstract = "As uveal melanoma originates in the neural crest, we aimed to explore whether somatostatin receptor (SSTR) expression is present and plays any role in these patients. Heavily pretreated metastatic uveal melanoma patients were tested with somatostatin receptor scintigraphy (SRS). Planar images of the whole body complemented by single-photon emission computed tomography on suspected sites were acquired between 4 and 24 h after an intravenous administration of 185-222 MBq (5-6 mCi) of indium-octeotride. SSTR expression in metastatic tissues was confirmed by immunohistochemistry. In seven patients, sandostatin LAR was used with therapeutic intention. Thirty white patients were tested. All had extensive metastatic disease and the median number of previous treatments was three. SRS was found to be positive in 14 (46{\%}) of the patients, but was not related to sex, type of previous treatments, tumor site, or histological type. In 10 patients, sufficient tumor specimens were available to perform immunohistochemical staining for SSTR. All cases with positive SSTR-2A staining were also positive by SRS. Two of the seven patients who received sandostatin LAR died within a month after receiving the first dose, whereas another two (28.5{\%}) had stable disease for more than 5 months. The median time to progression after starting sandostatin was 2.1 months (range: 0.2-5.5 months). Approximately 50{\%} of the uveal melanoma patients with extensive metastatic disease were positive for SSR, which was consistent with immunohistochemical staining for SSTR-2A. Therapeutic approaches targeting SSTR might be beneficial in patients with metastatic uveal melanoma.",
keywords = "Sandostatin, Scintigraphy, Somatostatin, Somatostatin receptor-2, Uveal melanoma",
author = "Valsecchi, {Matias E.} and Misti Coronel and Intenzo, {Charles M.} and Kim, {Sung M.} and Witkiewicz, {Agnieszka K.} and Takami Sato",
year = "2013",
month = "2",
doi = "10.1097/CMR.0b013e32835b70e9",
language = "English (US)",
volume = "23",
pages = "33--39",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma

AU - Valsecchi, Matias E.

AU - Coronel, Misti

AU - Intenzo, Charles M.

AU - Kim, Sung M.

AU - Witkiewicz, Agnieszka K.

AU - Sato, Takami

PY - 2013/2

Y1 - 2013/2

N2 - As uveal melanoma originates in the neural crest, we aimed to explore whether somatostatin receptor (SSTR) expression is present and plays any role in these patients. Heavily pretreated metastatic uveal melanoma patients were tested with somatostatin receptor scintigraphy (SRS). Planar images of the whole body complemented by single-photon emission computed tomography on suspected sites were acquired between 4 and 24 h after an intravenous administration of 185-222 MBq (5-6 mCi) of indium-octeotride. SSTR expression in metastatic tissues was confirmed by immunohistochemistry. In seven patients, sandostatin LAR was used with therapeutic intention. Thirty white patients were tested. All had extensive metastatic disease and the median number of previous treatments was three. SRS was found to be positive in 14 (46%) of the patients, but was not related to sex, type of previous treatments, tumor site, or histological type. In 10 patients, sufficient tumor specimens were available to perform immunohistochemical staining for SSTR. All cases with positive SSTR-2A staining were also positive by SRS. Two of the seven patients who received sandostatin LAR died within a month after receiving the first dose, whereas another two (28.5%) had stable disease for more than 5 months. The median time to progression after starting sandostatin was 2.1 months (range: 0.2-5.5 months). Approximately 50% of the uveal melanoma patients with extensive metastatic disease were positive for SSR, which was consistent with immunohistochemical staining for SSTR-2A. Therapeutic approaches targeting SSTR might be beneficial in patients with metastatic uveal melanoma.

AB - As uveal melanoma originates in the neural crest, we aimed to explore whether somatostatin receptor (SSTR) expression is present and plays any role in these patients. Heavily pretreated metastatic uveal melanoma patients were tested with somatostatin receptor scintigraphy (SRS). Planar images of the whole body complemented by single-photon emission computed tomography on suspected sites were acquired between 4 and 24 h after an intravenous administration of 185-222 MBq (5-6 mCi) of indium-octeotride. SSTR expression in metastatic tissues was confirmed by immunohistochemistry. In seven patients, sandostatin LAR was used with therapeutic intention. Thirty white patients were tested. All had extensive metastatic disease and the median number of previous treatments was three. SRS was found to be positive in 14 (46%) of the patients, but was not related to sex, type of previous treatments, tumor site, or histological type. In 10 patients, sufficient tumor specimens were available to perform immunohistochemical staining for SSTR. All cases with positive SSTR-2A staining were also positive by SRS. Two of the seven patients who received sandostatin LAR died within a month after receiving the first dose, whereas another two (28.5%) had stable disease for more than 5 months. The median time to progression after starting sandostatin was 2.1 months (range: 0.2-5.5 months). Approximately 50% of the uveal melanoma patients with extensive metastatic disease were positive for SSR, which was consistent with immunohistochemical staining for SSTR-2A. Therapeutic approaches targeting SSTR might be beneficial in patients with metastatic uveal melanoma.

KW - Sandostatin

KW - Scintigraphy

KW - Somatostatin

KW - Somatostatin receptor-2

KW - Uveal melanoma

UR - http://www.scopus.com/inward/record.url?scp=84872068475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872068475&partnerID=8YFLogxK

U2 - 10.1097/CMR.0b013e32835b70e9

DO - 10.1097/CMR.0b013e32835b70e9

M3 - Article

C2 - 23164993

AN - SCOPUS:84872068475

VL - 23

SP - 33

EP - 39

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 1

ER -